Patent · US Expired

Use of aryl N-substituted carboxamides directly and as radio-and chemosensitizers for killing tumor and cancer cells and novel compounds for such use

US6713517B1 · kind B1 · utility

0Cited by

15References

3Claims

0Family size

Assignee

OXiGENE, Inc. · US

Inventors

Ronald W. Pero · Lund, SE
Anders Olsson · Stockholm, SE
Tomas Ekberg · Lund, SE
Alan Schwartz · Clayton, US
David Chaplin · Aston Rowant, GB

Key dates

Filing date	Feb 27, 1997
Grant date	Mar 30, 2004
Priority date	—
Expiry date	Aug 8, 2018

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07C237/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Methods of killing tumor or cancer cells in human patients using an aryl N-substituted carboxamide having one or more aryl halo or one or more aromatic nitrogens, and/or acid addition salts thereof. The carboxamide may be an N-substituted nicotinamide or an N-substituted benzamide having such features, and may be used directly as a chemotherapeutic agent, or as a sensitizer for radiation or other chemotherapeutic agents. New compositions for such use include N-(2-diethylamino-ethyl)-4-amino-3-chlorobenzamide, N-(2-diethylamino-ethyl) nicotinamide, and their acid addition salts, e.g. hydrochlorides.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.